Literature DB >> 35748956

Surgical selection and prognostic analysis in patients with unilateral sporadic medullary thyroid carcinoma.

Jinming Zhang1, Pengfei Gu1, Dongmei Huang1, Jingzhu Zhao1, Xiangqian Zheng2, Ming Gao1,3,4.   

Abstract

PURPOSE: The extent of thyroid surgery and cervical lymph node dissection of unilateral sporadic medullary thyroid carcinoma (sMTC) is still controversial, and the aim of this study was to investigate whether hemithyroidectomy was adequate as a locally curative surgery for patients with unilateral sMTC.
METHODS: This study is a retrospective case series of patients with sMTC who underwent curative total thyroidectomy or hemithyroidectomy in our institution from January 2011 to December 2019.
RESULTS: In total, 129 patients who met the inclusion criteria were enrolled including 49 (38.0%) patients who underwent total thyroidectomy and 80 (62.0%) patients who underwent hemithyroidectomy. About 80 (62.0%) patients achieved a biochemical cure (BC), whereas there was no significant difference between two groups in biochemical cure rate (61.2% versus 62.5%, P = 0.885). A logistic regression analysis showed a strong negative correlation between the factors of preoperative calcitonin level and pTNM stage and biochemical cure. In the log-rank test, no significant difference in OS (P = 0.314) and DFS (P = 0.409) was found between the two surgical groups. Lateral cervical lymph node metastasis and pTNM stage were significant prognostic factors affecting DFS in univariate analysis; moreover, absence of biochemical cure, tumor size ≥ 4 cm and lateral cervical lymph node metastasis were independent risk factors of unilateral sMTC patients in our analysis.
CONCLUSION: For patients with unilateral sMTC, hemithyroidectomy was adequate as a locally curative surgery, because the patients underwent total thyroidectomy did not benefit more from it in the aspects of BC/OS/RFS, while the postoperative increasing incidence rate of postoperative hypocalcemia could not improve patients' quality of life.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biochemical cure rate; Carcinoma,medullary; Recurrence; Thyroid neoplasms

Year:  2022        PMID: 35748956     DOI: 10.1007/s00423-022-02591-9

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  36 in total

Review 1.  Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma.

Authors:  O Gimm; T Sutter; H Dralle
Journal:  J Cancer Res Clin Oncol       Date:  2001       Impact factor: 4.553

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  Thyroid cancer histological subtypes based on tumor size: National perspective.

Authors:  Zaid Al-Qurayshi; Megan J Foggia; Nitin Pagedar; Grace S Lee; Ralph Tufano; Emad Kandil
Journal:  Head Neck       Date:  2020-04-10       Impact factor: 3.147

Review 4.  Advances and controversies in the diagnosis and management of medullary thyroid carcinoma.

Authors:  H M Heshmati; H Gharib; J A van Heerden; G W Sizemore
Journal:  Am J Med       Date:  1997-07       Impact factor: 4.965

5.  Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register.

Authors:  F Raue; J Kotzerke; D Reinwein; S Schröder; H D Röher; H Deckart; R Höfer; M Ritter; F Seif; H Buhr
Journal:  Clin Investig       Date:  1993-01

6.  Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Authors:  Rossella Elisei; Barbara Cosci; Cristina Romei; Valeria Bottici; Giulia Renzini; Eleonora Molinaro; Laura Agate; Agnese Vivaldi; Pinuccia Faviana; Fulvio Basolo; Paolo Miccoli; Piero Berti; Furio Pacini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

Review 7.  Medullary thyroid carcinoma: recent advances and management update.

Authors:  D J Marsh; D L Learoyd; B G Robinson
Journal:  Thyroid       Date:  1995-10       Impact factor: 6.568

Review 8.  Surgery for lymph node metastases of medullary thyroid carcinoma: A review.

Authors:  Linda X Jin; Jeffrey F Moley
Journal:  Cancer       Date:  2015-11-05       Impact factor: 6.860

9.  Multifocality in Sporadic Medullary Thyroid Carcinoma: An International Multicenter Study.

Authors:  Garth F Essig; Kyle Porter; David Schneider; Debora Arpaia; Susan C Lindsey; Giulia Busonero; Daniel Fineberg; Barbara Fruci; Kristien Boelaert; Johannes W Smit; Johannes Arnoldus Anthonius Meijer; Leonidas H Duntas; Neil Sharma; Giuseppe Costante; Sebastiano Filetti; Rebecca S Sippel; Bernadette Biondi; Duncan J Topliss; Furio Pacini; Rui M B Maciel; Patrick C Walz; Richard T Kloos
Journal:  Thyroid       Date:  2016-10-11       Impact factor: 6.568

Review 10.  A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma.

Authors:  Masoumeh Mohammadi; Mehdi Hedayati
Journal:  Cell J       Date:  2016-09-26       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.